Clinical Trial Update: Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating camrelizumab in combination with chemoradiotherapy for locoregional nasal cavity and paranasal sinus cancers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasal Cavity Cancer
• Paranasal Sinus Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Nasal Cavity Cancer, Paranasal Sinus Cancer | Phase 2 | Status: UNKNOWN